Stem Cell Technology Showcased in Saudi Arabia, a Major Healthcare Market… K-Medicine to the World
[Digital Leading Company] MiracellLocal medical device market size: approximately 9 trillion won… Introducing proprietary new technology, “Smart M-Cell”Over 70 teams visited… Popular in hair loss and men’s healthFollowing European academia, Miracell enters the Middle East market in earnest… Participating in Germany’s “Medica 2025” from the 17th to the 20thStem cell specialist Miracell Co., Ltd. announced its participation in the “2025 Global Health Exhibition,” held at the Riyadh International Convention and Exhibition Center in Saudi Arabia from the 27th to the 30th of last month.Hosted by the Saudi Arabian Ministry of Health, the exhibition was themed “Invest in Health.” Global interest in regenerative medicine, including extending healthy lifespan, preventing chronic diseases, and delaying aging, garnered attention for the latest stem cell treatment technologies.This year’s exhibition attracted over 100,000 medical professionals and 2,000 companies from around the world, engaging in active exchanges and offering various workshops and sessions with over 500 speakers. In particular, key agenda items included digital health, AI-based diagnostics, preventive medicine, and the establishment of global partnerships, all aligned with the Saudi government’s Vision 2030 program for transforming the medical and healthcare industry. Miracell is accelerating its penetration of the Middle East market with the launch of its proprietary stem cell extraction system, “Smart Mcell.”Smart Mcell is currently being used in hospitals in Dubai, the United Arab Emirates (UAE), Kuwait, and elsewhere.Miracell is actively pursuing global marketing, participating in the international skin care exhibition “Dubai Derma” and touring key countries such as Qatar, Saudi Arabia, and Jordan. Park Tae-min, Director of Miracell’s Global Business Division, stated, “The Middle East, including Saudi Arabia, is rapidly expanding and localizing its healthcare industry. In particular, investment in premium healthcare in the areas of anti-aging, beauty, regeneration, and wellness is rapidly growing.” He added, “In a market with high demand for stem cell treatments, Miracell, known as the ‘King of Stem Cells’ and a leader in K-medical, participated in this exhibition to widely promote its technological prowess and discover new partners.” He continued, “During the event, approximately 70 teams, primarily from the Middle East, visited the Miracell booth, and there was strong interest in male energy and hair loss treatment.” He added, “Smart M-Cell concentrated CD34+ hematopoietic stem cells up to 282 times more efficiently than existing systems, with a cell viability rate of approximately 99%, generating explosive interest among Middle Eastern medical professionals.” The Saudi medical device market is expected to be worth approximately $6.42 billion (approximately KRW 9.3 trillion) in 2025 and grow to approximately $8.23 billion (approximately KRW 11.9 trillion) by 2030.With over 90% of its medical devices imported, the Saudi market presents significant opportunities, but also faces stringent regulations.Director Park explained, “Saudi Arabia places strict emphasis on safety and quality, making the medical device registration and approval process extremely rigorous. However, Miracell’s Smart M-Cell has been highly evaluated for its performance and safety among medical professionals, and is on the verge of entering the Saudi market.” Smart M-Cell is a biomedical device that isolates and concentrates stem cells and regenerative cells from blood or bone marrow for regenerative medicine. It has been designated as a New Excellent Technology (NET) by the Ministry of Health and Welfare and registered with the U.S. Food and Drug Administration (FDA). It is currently being used in various clinical areas, including knee osteoarthritis and anti-aging treatments. Miracell’s SmartMcell is already attracting attention in the European market. At the European Symposium on Regenerative Medicine held in Serbia last September, Dr. Vladimir Jovanović (a regenerative medicine expert under the Serbian Ministry of Health) and Dr. Yelena presented the results of a three-year clinical trial using SmartMcell, drawing attention and being broadcast on national television. Furthermore, at the World Pain Congress held in Spain last October, Greek hematologist Dr. Ilias Theodoropoulos announced, “We have demonstrated the efficacy of SmartMcell stem cell therapy in treating rheumatic pain and anti-aging through over 400 cases of SmartMcell stem cell therapy over the past year,” drawing attention from the global academic community.Miracell plans to further strengthen its position in the Middle East market through this Saudi exhibition and to showcase SmartMcell’s technological prowess and clinical competitiveness to the world by participating in Medica 2025, the world’s largest medical device exhibition, held in Düsseldorf, Germany, from the 17th to the 20th. Meanwhile, Miracell has developed and launched the world’s first light energy cell activation bio-equipment, the “Chroma M-Cell” ringer bag cover. The device can be tailored to a patient’s symptoms with four color wavelengths, helping to improve cell condition and enhance efficacy and stability during stem cell treatments. Source: Donga Ilbo (https://www.donga.com/news/Health/article/all/20251110/132725721/2)
Miracell Develops ‘Chroma Mcell,’ the World’s First Light-Energy-Powered Ringer Bag Cover
Shining Light on Cells to Maximize Physiological Activity… Next-Generation Cell Care System, ‘Chroma M-Cell’ Launched Non-invasive treatment using light to stimulate cells. Four color wavelengths for specific symptomatic applications… Under investigation by hospitals in over 50 countries. Miracell, a stem cell specialist, announced the development and launch of ‘Chroma M-Cell,’ a next-generation cell care system utilizing photobiostimulation technology.Chroma M-Cell, a system used in conjunction with Miracell’s stem cell separation and concentration equipment, ‘Smart M-Cell,’ is an advanced cell care solution that maximizes cellular physiological activity by irradiating extracted cells with customized light energy. Chroma M-Cell is an ‘LED light source irradiation device for ex vivo photobiomodulation of cell-containing biological fluids,’ helping to improve cellular condition and enhance the efficacy and safety of stem cell treatments.Its one-touch operation allows medical professionals to easily use the system, and the ability to select from four color wavelengths based on patient symptoms and treatment objectives offers high usability. Care for cells with light… Scientifically Evidence-Based PhotobiomodulationRecent research suggests that light has a biological regulatory function that goes beyond mere illumination.The 2023 paper by Ishihara, Courville, and Chen, “The Complex Effects of Light on Human Metabolism,” revealed that light profoundly influences overall physiological functions, including circadian rhythms, hormones, mental health, metabolism, immunity, and skin health.The 2025 paper “Mechanisms and Applications of Photobiomodulation,” published in Zero Science, also explains that photobiomodulation can contribute to maintaining tissue homeostasis and delaying aging by modulating intracellular and extracellular receptors and growth factors.Based on this scientific background, Miracell developed Chroma M-Cell, under the philosophy that “light is the source of stem cell vitality.” Shin Hyun-soon, CEO of Miracell, explained, “I’ve always felt chilled when receiving cold IV fluids during intravenous injections.I’ve long thought it would be beneficial to reduce the chill when receiving stem cell Ringer’s solutions, and I’ve been contemplating a method for a long time. After much trial and error, I’ve worked with researchers to develop the system we call Chroma Mcell.” She continued, “Croma Mcell is the world’s first product to irradiate stem cell Ringer’s solutions with light energy in three dimensions, optimizing cell health. Since its launch, it has received enthusiastic responses from patients and medical professionals alike, as it helps stabilize the unstable state of cells exposed to the external environment.” Croma Mcell offers five product lines and four wavelengths, allowing for customized treatment options tailored to each patient’s individual needs. Red light (660 nm) penetrates deep into the skin layers, restoring collagen and tissue. Blue light (460-475 nm) acts on the epidermis, providing antibacterial and acne-fighting benefits. Yellow light (585-590 nm) stimulates the circulatory system, reducing swelling, redness, and improving blood flow. Green light (525-530 nm) has immune and detoxifying effects, restoring liver function and enhancing immunity. Safe Cell-Care Technology Leads the Global Biomedical Device Market Chroma M-Cell is a non-invasive treatment method that stimulates cells using only a light source. Designed with safety and convenience in mind, it can be integrated with various medical and aesthetic procedures.CEO Shin stated, “Chroma M-Cell is not simply a light therapy device; it is a cutting-edge cell-care platform that maximizes the synergy of stem cell therapy. Over 50 countries have already expressed interest in introducing it.” Miracell will continue to focus on developing technologies that drive innovation in cell-based treatments. Meanwhile, Miracell is expanding its presence in the global biomedical device market, attracting attention from medical professionals and buyers in various regions, including Europe, the Middle East, and North America, for its stem cell technology.Miracell plans to participate in the Gynecology Conference in Dubai on the 3rd and 4th of next month, followed by MEDICA, the world’s largest medical device fair, in Düsseldorf, Germany, from the 17th to the 20th, to promote its Smart Mcell and Chroma Mcell systems. Source: Donga Ilbo (https://www.donga.com/news/Health/article/all/20251028/132646638/2)
Miracell’s Smart M-Cell clinical results draw attention at the European Regenerative Medicine Symposium.
Miracell Draws Attention at European Regenerative Medicine Symposium with Clinical Results of ‘Smart M-Cell’ Miracell, a stem cell specialist, participated in the European Regenerative Medicine Symposium held at the Metropol Palace Hotel in Belgrade, Serbia, on the 30th of last month. It demonstrated the clinical efficacy of its cutting-edge stem cell extraction device, ‘Smart M-Cell,’ drawing attention from the European medical community. The symposium, hosted by Miracell’s European partner, ‘New Medical Technologies,’ brought together physicians from Serbia, Sweden, Croatia, Turkey, Hungary, Romania, and other key partner countries, as well as from around the world, fostering a vibrant academic exchange. Dr. Vladimir Jovanovic is an orthopedic surgeon and traumatologist recognized as a leading figure in the field of regenerative medicine in the Balkan region.Having introduced and clinically utilized SmartMcell since 2023, he presented at this symposium on “Stem Cell-Based Treatment of Hip and Knee Osteoarthritis: The Effects of Combination with Nanoscopy-Assisted Treatment.” Dr. Jovanovic is a member of the National Expert Committee on Regenerative Medicine under the Serbian Ministry of Health and serves as President of the Association for Intra-Articular and Regenerative Therapies. Dr. Dusan Maric (Orthopedic and Pediatric Surgery) of the University of Novi Sad Medical School presented “Placental Stromal Cell-Based Treatment for Acute Inflammatory Diseases and Cytokine Storm Countermeasures” and highlighted the potential of stem cell-based anti-inflammatory treatments. Dr. Maric is the founder of the South Eastern European Association for Regenerative Medicine (SEEBRA) and is actively researching the application of cell therapy in orthopedics. Dr. Branko Barak (rheumatologist, internal medicine, and regenerative medicine specialist) presented on “A New Treatment Paradigm for Knee Osteoarthritis Combining Mesenchymal Stem Cells and Extracellular Matrix,” while Professor Boya Pavlović (PhD, Hematology) presented on “The Regenerative Potential of Stem Cells and the Possibility of Intravenous Injection.” Dr. Yelena Jovanović, a renowned clinician specializing in the treatment of rheumatic diseases in the field of physical medicine and rehabilitation, presented on “Synergy between Biological and Physical Therapy—Enhancing Functional Recovery in Stem Cell Therapy Patients,” highlighting the potential clinical application of stem cells in rehabilitation therapy. Following the speakers’ presentations, the symposium also featured a hands-on demonstration of the SMART M-CELL system, which garnered significant attention.Smart M-Cell is a cutting-edge system that automatically extracts and concentrates stem cells from blood or bone marrow, boasting cell viability rates of up to 99%.It is recognized as an optimal solution for personalized treatment, as it can simultaneously extract more than five key regenerative cell populations, including growth factors, white blood cells, and SDF-1α. Richard Benitez of Miracell’s Overseas Business Division stated, “After successfully completing stem cell treatment with a partner hospital in Budapest, Hungary,I was invited to attend this symposium as a special guest. The symposium generated such strong interest and response in Europe that the Serbian state-run broadcaster PRVA TV even traveled to cover the event.” He emphasized, “The clinical case presentations by Dr. Vladimir and Dr. Yelena, who have treated numerous patients with SmartMcell over the past three years, were highly praised by medical professionals worldwide. This demonstrates the global recognition of the effectiveness of Miracell’s stem cell technology.” Miracell plans to use this Serbia symposium as an opportunity to strengthen joint collaboration with key partner countries, including Croatia and Romania, and actively pursue additional symposiums in Europe. Source: Donga Ilbo (https://www.donga.com/news/Health/article/all/20251010/132535143/1)
Stem Cell-Based Regenerative Medicine Leads to a Paradigm Shift in Gynecological Treatment
Miracell Hosts the 38th CGP Academy With stem cell-based regenerative therapies garnering attention in the field of improving women’s health, Professor Lee Eun-sil of the Department of Obstetrics and Gynecology at Soonchunhyang University Seoul Hospitaldelivered a lecture on “Gynecological Applications of Stem Cells (CD34+) and BSCs” to obstetricians and gynecologists at the CGP Academy hosted by Miracell Co., Ltd. on the 20th of last month. Degeneration or damage to the reproductive organs, including the uterus, vagina, and vulva, is a common problem after menopause. Common examples include vaginal atrophy, endometrial damage, and decreased sexual function. Furthermore, degenerative changes in bladder tissue due to aging weaken pelvic floor muscles, leading to bladder sagging, decreased urinary function, and urinary incontinence.In her lecture, Professor Lee highlighted the potential of regenerative medicine approaches to address these issues. In his lecture, Professor Lee explained the mechanism of action, saying, “Stem cells are effective in regenerating damaged tissues and restoring function.CD34+ cells contain various growth factors and cytokines, including stem cells, which stimulate tissue regeneration, angiogenesis, cell migration, differentiation, and proliferation.In particular, they are rich in white blood cells, making them particularly effective in antibacterial action and immune regulation.” He continued, “He emphasized the potential benefits of stem cell utilization on the health of the female reproductive system, highlighting key areas where endometrial regeneration, enhanced receptivity, and increased clinical pregnancy rates are anticipated.” Professor Lee Eun-sil explained, “SMART M-CELL can manufacture CD34+ stem cells, which play a crucial role in angiogenesis.” “The CD34+ marker is primarily found in hematopoietic stem cells and vascular endothelial progenitor cells. When whole blood was treated with SMART M-CELL, CD34+ concentration increased by approximately 5-6 times,and growth factors such as VEGF and PDGF increased by 2-3 times compared to whole blood.” He continued, “CD34+ HSCs (blood stem cells) can differentiate into all blood cells, and CD34+ EPCs (vascular endothelial progenitor cells) are mobilized to damaged blood vessels,forming new blood vessels, repairing existing ones, and promoting tissue regeneration.”“In other words, CD34+ cells are the source cells that produce blood cells and blood vessels, and are involved in tissue regeneration, angiogenesis, and immune regulation, contributing to skin regeneration, immune response regulation, inflammation suppression, and tissue repair.” Professor Lee emphasized the effectiveness of regenerative medicine treatments, citing numerous clinical cases and research papers. “Clinical Evaluation of Autologous Platelet-Rich Plasma Injection in Postmenopausal Vulvovaginal Atrophy: A Pilot Study (2022)” After two PRP injections in 47 women with postmenopausal vulvar and vaginal atrophy,“significant improvements were observed in Vaginal Health Index (VHI) and Vulvar Symptom Questionnaire (VSQ) scores, and no major adverse effects were reported.” Professor Lee Eun-sil emphasized the treatment mechanism, saying, “CD34+ stem cell injection induces angiogenesis, improving blood flow within tissues. Endothelial regeneration and increased mucosal vascular density enhance oxygen and nutrient supply to tissues. Furthermore, the regenerative effect is promoted by the cytokines and growth factors secreted by stem cells.” He continued, “Stem cell (CD34+) injections are minimally invasive and highly safe because they utilize autologous material.” He added, “CD34+ stem cells promote tissue regeneration, enhance collagen production,stimulate new blood vessel formation, and reduce inflammation. They have potential therapeutic effects for a wide range of gynecological problems, including vaginal dryness, stress urinary incontinence, bladder pain syndrome, and improved sexual function.” At the academy, Dr. Kim Tae-ryun of Selfia Clinic performed stem cell treatment on PYAGAY KLYOSHA (73 years old, Russia), a foreign patient with degenerative bladder disease who complained of urinary incontinence and vaginal dryness. This non-surgical approach, incorporating cellular medicine to improve aging bladder function, helps alleviate symptoms. Domestic stem cell treatments are so popular overseas that they are even attracting medical tourism. Source: Edaily (https://www.edaily.co.kr/News/Read?newsId=03398086642328984&mediaCodeNo=257&OutLnkChk=Y)
Stem Cell App ‘Celldoc’… Everything from Treatment Information to Hospital Appointments All in One Place
Miracell Co., Ltd., which supplies its stem cell extraction medical device, “Smart Mcell,” and blood and bone marrow kits to over 600 hospitals and clinics worldwide, has launched “Celldoc,” a stem cell treatment community platform.With the launch of Celldoc, a stem cell community platform connecting B2B (business-to-business) and B2C (business-to-consumer) channels, patients can access accurate information on stem cell treatments and easily access everything from stem cell clinic appointments to treatment. Miracell developed the app in response to the growing consumer interest in regenerative medicine and the increasing efficacy and safety of stem cell treatments driven by new medical technologies. Despite this, demand has grown, leading to a lack of relevant information. Miracell CEO Shin Hyun-soon explained, “Since 2007, Miracell has contributed to the nation’s health with stem cell reverse aging treatments for rare and intractable diseases, hair loss, skin, and plastic surgery. Many people still travel overseas to Japan and China for stem cell injections, but many overseas locations use cultured cells, which carry risks such as cell mutation and contamination.Safety must be a top priority when choosing a treatment that uses freshly extracted, concentrated cells directly injected into the body without culturing them.” He added, “We have launched the first stem cell-specific app to provide medical consumers with verified stem cell treatment information.” Celldoc, which stands for “Cell Doctor,” is a personalized total healthcare solution that contains all the information on stem cell treatments. It offers answers to questions about stem cells, remote consultations with medical professionals, and convenient reservations at each hospital. Patients can directly order kits for stem cell treatment and skin care procedures through the app, and receive the treatment at a designated hospital. All of Celldoc’s affiliated hospitals use proven stem cells and adhere to the principle of quantitative treatment.These hospitals utilize the “Smart M-Cell” stem cell extraction system developed by Miracell and its dedicated kits.Smart M-Cell has undergone an equivalence evaluation with the stem cell extraction equipment from Smart Prep, the US company that also treated golfer Tiger Woods’ knee, and has received approval from the Ministry of Food and Drug Safety.The treatment utilizes highly concentrated stem cells with a cell viability rate of over 99%, along with at least five multi-cell components essential for regeneration, including growth factors, ensuring safety. CEO Shin stated, “Hospitals and clinics using Smart M-Cell, known for its high cell viability and recovery rates, are sharing their medical information on Celldoc, raising high expectations from both doctors and consumers.” “The Celldoc platform lists over 500 hospitals and clinics, categorized by region and symptom, and connects patients directly to the appropriate hospital during consultations. This system will reduce indiscriminate medical shopping and popularize stem cell treatment.” Through Celldoc, patients can receive the same high-quality stem cell treatment at any hospital nationwide.The app provides preemptive information on stem cell treatment, enhancing patient understanding and enabling efficient medical services.Celdoc offers personalized treatments for knee arthritis, skin, hair loss, anti-aging, and more, utilizing SmartMcell’s unique stem cell extraction. Furthermore, Celldoc-affiliated hospitals and clinics can order kits and check inventory in real time through the app.Celdoc membership is free, and group purchases offer hospitals benefits. The app is available for Android, with iOS scheduled to launch in about a month. Miracell’s stem cell effects are recognized internationally, fueling a boom in preventive medicine. Dr. Theodoropoulos Ilias, a hematologist from Greece, presented the therapeutic effects of SmartMcell at the “2024 IV CONGRESO SEMDOR VALENCIA,” hosted by the Spanish Society of Pain Medicine.Dr. Ilias stated that he has personally treated over 400 patients, including those receiving intravenous injections, using SmartMcell over the past year, demonstrating excellent treatment effects and plans to write a paper based on these findings. Currently, Miracell shares stem cell information with hospitals in over 40 countries using SmartMcell, including Greece, Austria, and Spain, through the medical platform “Celphia Global Platform (CGP).” Miracell plans to upgrade Celldoc to a global medical system by connecting with hospitals and clinics in each country. CEO Shin stated, “Celdoc also serves as a medical tourism platform, which is expected to attract many international patients to our member hospitals. I recently met with the president of the Indonesian Women Entrepreneurs Association, and many member companies expressed their willingness to visit Korea for medical tourism through Celldoc. We anticipate that this will be the starting point for many international patients seeking stem cell treatment in Korea. We aim to reach over 5,000 hospitals worldwide, and we will expand Celldoc into a world-class medical platform and global app.” Meanwhile, Miracell is a leading company in stem cell and cell therapy, holding the most approvals from the Ministry of Food and Drug Safety.In July 2023, the government directly registered a new medical technology for intra-articular injection of bone marrow aspirate concentrate for knee osteoarthritis using Smart Mcell, recognizing its efficacy. In 2012, Miracell also registered stem cell treatments for cartilage defects, and in 2013, for acute myocardial infarction and critical limb ischemia, and these treatments are now being used in hospitals. Source: Dong-A Ilbo (https://www.donga.com/news/Health/article/all/20250415/131414005/2)
Miracell to Participate in IMCAS 2025 in Paris, Introducing “Smart M-Cell,” a Stem Cell Extraction System
Stem cell specialist Miracell announced on the 4th that it participated in the “IMCAS World Congress 2025,” held in Paris, France from January 30th to February 1st,exhibiting its stem cell extraction medical device, “Smart Mcell,” and its dedicated kit. IMCAS, held annually since 1994, is the world’s largest conference on aesthetic medicine. It brings together experts from various fields, including dermatology, plastic surgery, and aging science, to share the latest medical technologies. This year’s conference brought together over 370 companies and 1,000 speakers from 136 countries, attracting over 18,000 visitors. This year’s IMCAS highlighted cutting-edge technologies and research in a variety of fields. Lectures covered topics such as live augmentation surgery and anatomy, complication management, laser and EBD updates, facelift masters, and bio-regenerative technologies. Key topics of interest included medical and surgical approaches to hair and the diagnosis of pigmented lesions. Miracell, which actively conducts clinical research on stem cell therapy in collaboration with university hospitals and other domestic and international medical institutions, exhibited its “Smart M-Cell” stem cell extraction system at this conference,and showcased its innovative technology aimed at specializing in safe stem cell therapy. Miracell’s “Smart M-Cell” selectively concentrates and extracts essential cells for regeneration, including stem cells, growth factors, red blood cells, white blood cells, and SDF-1α, demonstrating its potential for personalized treatment. Shin Hyun-soon, CEO of Miracell, stated, “Regenerative medicine stem cell treatments are gaining attention as a treatment option to improve health and quality of life in an aging society. The announcement of the clinical efficacy of Smart M-Cell at a European conference last year fueled increased interest from global buyers.” “Medical professionals using Smart M-Cell from Germany, Spain, and Greece visited our booth to introduce Miracell’s technology.” CEO Shin then revealed his future plans, saying, “Smart Mcell’s excellent performance is recognized by medical professionals overseas. We will introduce K-regenerative medicine stem cell extraction technology to more countries and lead the global stem cell treatment field.” Source: Economy Science (https://www.e-science.co.kr)
Miracell to Exhibit ‘Smart M-Cell’ at Korea Life Science Week 2024… “Leading the Global Stem Cell Treatment Field!”
Miracell Co., Ltd. (CEO Shin Hyun-soon) participated in “KOREA LIFE SCIENCE WEEK 2024 & KOREA LAB Autumn 2024,” held at COEX in Seoul from Tuesday, November 12th to Thursday, November 14th. With the goal of specializing in “safe stem cell therapy,” Miracell has consistently collaborated with domestic and international medical institutions on research and development (R&D) and has adopted advanced medical technologies.Based on its experience in stem cell research, which began in earnest in 2009, Miracell has introduced stem cell therapies, cosmetics, and medical devices for conditions such as severe limb ischemia (Buerger’s disease, diabetic foot, etc.), acute myocardial infarction, osteophytes, and osteoarthritis. Notably, last year, Miracell received certification as a new medical technology (Ministry of Health and Welfare) for its bone marrow stem cell injection therapy for knee osteoarthritis. At this exhibition, Miracell showcased its “Smart M-Cell,” a biomedical device that collects stem cells from bone marrow and blood. This device was previously designated and certified as an innovative medical device and a New Excellent Technology (NET), demonstrating its outstanding competitiveness.Functioning on a principle similar to a centrifuge, the Smart M-Cell selectively and effectively extracts and concentrates stem cells, red blood cells, white blood cells, platelets, and growth factors.Company officials explained that the cells obtained using this method can be highly utilized in personalized treatments. Compared to autologous platelet-rich plasma (PRP) devices commonly used in the medical field, Miracell can handle significantly larger volumes of bone marrow and blood simultaneously. As the sample volume increases, the number of effective cells obtained also increases proportionally. It has also proven its superior extraction efficiency across various criteria. A Miracell representative stated, “We are leading the global development of stem cell therapy and advanced regenerative medicine by gradually expanding the global supply of Smart Mcell, as well as BmSC and BSC kits developed based on our original technology.” “Stem cell therapy is gaining recognition as a treatment option to improve human health and quality of life, particularly in developed countries, addressing the rapidly aging population. Therefore, interest and expectations for our company are growing.” The company continued, “Miracell plans to successfully complete US FDA approval for its BmSC kit, currently in the process, and establish itself as a world-class company in the stem cell market.” “Furthermore, as one of the leading companies in Korea’s biotechnology industry, our goal is to continue to grow.” Meanwhile, Korea Life Science Week 2024, held in conjunction with KOREA LAB Autumn 2024 (International Research Experiment and R&D Convergence Advanced Science and Technology Exhibition), showcased the latest technologies and products in the fields of pharmaceuticals and biohealth, advanced biotechnology, regenerative medicine, convergence medical technology, experimental and analytical equipment, and research and development (R&D) equipment. Furthermore, various forums and seminars were held concurrently, where industry experts and researchers discussed the latest technological trends and strategies. Source: AVING (https://kr.aving.net)
Stem Cell Therapy Solution, Korea’s Only Ministry of Health and Welfare Certified
MiracellProven Effective in Critical Lower Extremity Ischemia and Cartilage Deficiency Since 2007, Miracell has been conducting collaborative research with domestic and international medical institutions to specialize in safe stem cell therapy. Miracell has dedicated itself to stem cell development, contributing to the nation’s health through advanced medical technology. As a result, Miracell is the only company in Korea to receive New Technology and New Medical Technology certifications from the Ministry of Health and Welfare for stem cell therapy. Miracell’s stem cell solutions have proven to be highly effective in treating bone marrow stem cell-based conditions such as critical lower extremity ischemia, acute myocardial infarction, cartilage defects, and knee osteoarthritis. Since receiving New Medical Technology certification from the Korea Evidence-Based Healthcare Collaborating Agency (NECA) in July 2023, Miracell has been using its bone marrow stem cell products (Smart Mcell, BmSC kit, BSC) at approximately 580 hospitals and clinics in Korea, including large general hospitals such as Severance Hospital, Seoul St. Mary’s Hospital, and Ewha Womans University Mokdong Hospital. The company exports its products to 38 countries. Recently, doctors and stem cell experts from Spain, Dubai, and the Philippines visited Miracell to learn about its treatment techniques and toured its factory. Currently, hospitals in Europe, including Sweden, Austria, Greece, Italy, and Turkey, are importing and using Miracell products. At the “2024 IV CONGRESO SEMDOR VALENCIA” conference, hosted by the Spanish Pain Society on the 25th of last month, Dr. Theodoropoulos Ilias, a hematologist from Greece, presented the results of approximately 400 cases treated directly with Miracell Smart Mcell. Dr. Ilias announced that Miracell stem cell treatment has shown excellent results. Miracell is planning to expand its Miracell production plant in the Osong Industrial Complex to meet the rapidly increasing demand for its products following its new medical technology certification. To achieve this, Miracell is currently pursuing an IPO on the Korea Exchange and plans to quickly raise funds to build a new production facility once the listing is completed. The blueprint for the new plant has been developed and construction permits have been obtained. Miracell is securing core stem cell technology, including domestic and international patent applications for stem cell extraction and treatment technologies. Miracell’s SmartMcell, a stem cell treatment, has completed registration with the US Food and Drug Administration (FDA), and the BmSC kit is also seeking FDA registration. In Europe, both the device (SmartMcell) and the BmSC and BSC kits have received CE certification and are currently exporting. Miracell is leading the global development of stem cell therapy and advanced regenerative medicine.Last May, Miracell was selected as a promising company in the “2024 Global Small and Medium Enterprise 1000+ Project” by the Ministry of SMEs and Startups. With stem cell therapy expanding in the face of a super-aging society, Miracell plans to contribute to improving public health and solidify Korea’s position as a biotechnology powerhouse by promoting Korea’s biotechnology technology globally. [Dong-A Ilbo, Reporter Cho Seon-hee] Source: https://www.donga.com/news/Health/article/all/20241105/130359390/2
Miracell to Participate in the Spanish Pain Society’s IV SEMDOR 2024
Dr. Ilias of Greece Announces the Effectiveness of ‘SMART M-CELL’ Treatment Miracell, a stem cell company, announced on the 31st that it participated in the ‘2024 IV CONGRESO SEMDOR VALENCIA,’ hosted by the Spanish Pain Society and held at the Sercotel Sorolla Hotel in Valencia, Spain, for three days from October 24th.‘CONGRESO SEMDOR 2024’ is a medical conference where pain treatment experts meet to exchange knowledge, share experiences, and explore the latest research and developments in the field of pain treatment.This year’s theme was ‘Advancements in Pain Treatment: Innovation, Interdisciplinarity, and Quality of Care.’ Presenters included physicians from Spain, the UK, the US, the Netherlands, Canada, Greece, and Italy, with presentations focused on finding effective solutions to prevent and treat pain. Miracell was invited to participate in this conference by Spanish buyer SIEBEN and the Spanish Society of Pain Medicine (SEMDOR). It showcased its stem cell extraction system, SMART M-CELL, and its dedicated kit, drawing significant attention from doctors from around the world. On the 25th, Dr. Theodoropoulos Ilias, a doctor of hematology from Greece, and Dr. Luis Miguel Torres, an associate professor at the University of Cadiz in Spain and a specialist in regenerative medicine and pain management, presented a workshop titled “Workshop on General Stem Cell Management in Regenerative Medicine.” They presented on the differences between IV and stem cell therapy, as well as the therapeutic applications and clinical efficacy of Miracell’s “SMART M-CELL,” capturing the attention of attending doctors. Dr. Ilias stated, “After implementing Smart M-Cell, I received an intravenous stem cell injection to experience it firsthand. Even though it wasn’t a local injection, my previously unpleasant back pain disappeared and I felt a significant improvement in my health.” He continued, “Over the past year, I’ve treated over 400 patients with stem cells, including IV injections. Having personally witnessed the remarkable results, I want to share the remarkable regenerative power and effective therapeutic effects of stem cells.” “I will also write a paper based on the clinical treatment data so far.” Miracell plans to collaborate with Dr. Ilias to gather patient treatment data from countries where Smart M-Cell is being used, share opinions on clinical effects, and organize a global conference where they can present their findings. Meanwhile, SIEBEN, a medical device distribution company that has signed an exclusive import contract for SmartMcell in Spain, stated, “With the performance and therapeutic effects of SmartMcell being showcased at this year’s Spanish Pain Congress, many hospitals are expressing interest in introducing it.” They added, “It is currently being supplied to several hospitals, including university hospitals. Following coordination with Miracell on import customs clearance schedules, distribution in Spain is expected to begin in earnest early next year.” Source: Medical Today (https://mdtoday.co.kr/)
No Nucleated Cells Found in Bone Marrow Extraction Using Blood Kit for Knee Stem Cell Injection
Bone marrow stem cell injections for knee arthritis are a treatment that uses stem cells from the body to improve the knee environment. They are popular with patients suffering from severe knee pain or seeking to slow the progression of arthritis. By selectively selecting high-quality stem cells necessary for tissue regeneration and injecting them into the knee, therapeutic effects can be expected. The stem cell extraction system plays a crucial role in this process. Most hospitals and clinics performing bone marrow stem cell injections use approved bone marrow processing devices. However, some medical device manufacturers have rebranded blood processing devices (PRP kits) as bone marrow processing devices, requiring caution. According to Dr. Kebby of the Harvard University Institute for Immunological Diseases, “Bone marrow contains a population of nucleated cells at various stages of development. These cells vary in density, but when PRP kits are used to isolate and concentrate bone marrow extracts, the nucleated cells essential for regeneration are virtually uncaptured.” [Harvard University IDI Institute Results Letter] In other words, the cell composition and density of blood and bone marrow differ, requiring the use of a dedicated kit tailored to the treatment. Otherwise, the absence of nucleated cells, which play a key role in regeneration, makes it difficult to expect effective treatment for knee arthritis. To maximize the effectiveness of knee arthritis injections, it’s important to verify that both the stem cell extraction medical device and the bone marrow kit are approved for stem cell use.It’s important to ensure that the device used has been validated by the Ministry of Food and Drug Safety for stem cell efficacy and that the correct dose of 10cc of concentrated cells, including stem cells, is injected.Miracell’s SMART M-CELL has undergone an equivalence evaluation with the US-based SmartPrep stem cell extraction device.In addition to receiving MFDS approval, the stem cell system has been recognized by the government for its superior stem cell extraction capabilities, earning it designation as a New Health Technology NET and an Innovative Product by the Public Procurement Service. Intra-articular injection of bone marrow aspirate concentrate for knee osteoarthritis (Notice No. 2023-128, 918) was also directly registered by Miracell and recognized as a safe and effective new medical technology for treating knee joint pain and improving function. [Edaily, Reporter Lee Soon-yong] Source: https://www.edaily.co.kr/News/Read?newsId=03463686639016840&mediaCodeNo=257&OutLnkChk=Y